# INTERMITTENT FASTING AND CANCER

Exploring Approaches, Potential Benefits, and Finding What Works Best For You

INDEPENDENT™ MEDICAL ALLIANCE

# Fasting for Cancer: A Holistic Approach

Fasting and intermittent fasting have gained significant attention in recent years—not only as tools for metabolic health and longevity, but also as potential complementary strategies in cancer care. Emerging research and anecdotal evidence suggest that periods of controlled fasting may help improve treatment outcomes, reduce side effects of chemotherapy, and support the body's natural healing processes. These benefits are thought to stem from fasting's ability to reduce inflammation, promote cellular repair (autophagy), enhance immune function, and potentially make cancer cells more vulnerable to treatment while protecting healthy cells.

However, fasting during cancer treatment is not a one-size-fits-all solution. Cancer patients often face complex nutritional and energetic needs, and fasting—if done improperly—can lead to unintended consequences such as weight loss, nutrient deficiencies, or weakened immunity. That's why it's essential to approach this practice with care, intention, and expert guidance.

This guide is designed to provide foundational knowledge about fasting and intermittent fasting as it relates to cancer, whether as a supportive therapy during active treatment or as part of a long-term healing plan. It is recommended that patients work with a qualified integrative or holistic practitioner—such as a naturopathic oncologist or functional medicine doctor—who understands both the medical and nutritional complexities of cancer care. With the right guidance, fasting can be a powerful ally in your healing journey.

# What “Fasting” Can Mean in Oncology

**Nightly circadian fast (12–14 hours):**
For example, finishing dinner at 7:00 pm and eating breakfast at 8:00–9:00 am. This is the most feasible form of fasting, aligns with circadian biology, and observational research suggests that fasting for ≥13 hours nightly may improve metabolic markers and potentially reduce cancer recurrence risk.

**Time-restricted eating (TRE 14:10 or 16:8):**
In this approach, food is consumed within an 8–10 hour window daily. Early cancer studies suggest this is feasible and can improve metabolic health, though oncology-specific research is still developing.

**Intermittent calorie restriction (e.g., 5:2):**
This involves two low-calorie days per week, with normal intake on the others. It has been studied far less in active cancer care but is a common fasting model in general health research.

**Short-term fasting (STF) around treatment:**
Typically a 24–72 hour fast using water or very minimal calories before (and sometimes after) chemotherapy. Early trials show promise in reducing treatment-related toxicity and protecting healthy cells, but adherence is challenging and safety requires close supervision.


**Fasting-mimicking diet (FMD):**
A very low-calorie, low-protein, plant-based protocol lasting about 3–4 days, often beginning before chemotherapy. Clinical trials in breast cancer suggest feasibility, reduced side effects, and potential improvements in treatment response. It is considered safer and more practical than water-only fasting.

**Prolonged water fasts (>3–5 days):**
Not recommended in oncology outside of carefully supervised medical programs due to significant risks including electrolyte imbalance, malnutrition, and refeeding syndrome. Reviews emphasize the difficulty and potential dangers relative to benefits.

**Juice fasts:**
Not considered true fasting, since juices are often high in sugar and low in protein and fiber. No clinical evidence supports their use in cancer care, and unpasteurized juices can be unsafe for immunocompromised patients. Whole fruits and vegetables within balanced meals are safer, more effective alternatives.

# Why Fasting is Being Studied (Mechanisms)

**Metabolic switching:**
During fasting, the body shifts from glucose to ketones as a primary energy source. This lowers glucose, insulin, and IGF-1 levels, creating a metabolic environment that may stress tumor cells while supporting repair processes in healthy cells.

**Differential stress resistance/sensitization (DSR/DSS):**
Research suggests fasting can protect normal cells from the stress of chemotherapy while at the same time making cancer cells more vulnerable. This effect has been consistently shown in animal studies and is beginning to be supported in early human trials.

**Autophagy and immune effects:**
Fasting can stimulate autophagy, the body's natural cellular recycling process, which may help remove damaged cells and regulate inflammation. It also appears to influence immune activity in ways that may support anti-tumor defense. However, autophagy can have both protective and harmful roles depending on the cancer type and stage, so clinical application must be carefully considered.

# What the Human Evidence Says Right Now

**During Treatment (Especially Chemotherapy)**

Fasting-Mimicking Diet (FMD) with chemotherapy: Randomized data, including a large breast cancer trial, show FMD to be feasible, with signals of reduced treatment-related toxicity and possible improved tumor responses. More phase III studies are underway.

Recent randomized trials (2024) and smaller studies: Cyclic FMD during neoadjuvant chemotherapy has shown reduced gastrointestinal and blood-related toxicities, improved metabolic parameters, and good adherence.

Short-term fasting (24–72 hours, water or very low calories) around chemotherapy: Small studies suggest reduced DNA damage in normal cells and fewer side effects. However, adherence and safety remain challenging, making FMD generally preferred over strict water-only fasting.

Systematic and narrative reviews (2022–2024): Overall, fasting strategies show promise in reducing side effects and improving quality of life during treatment. Still, larger, well-controlled trials are needed to standardize protocols and determine which patients benefit most.

Survivorship & Prevention: Nightly fasting of 13 hours or longer is associated with better metabolic markers and lower recurrence signals in breast cancer observational studies. While not definitive, this suggests that circadian fasting may play a preventive role.

Immunotherapy (Preclinical): In animal models, FMD cycles combined with immune checkpoint blockade slowed tumor growth and reduced cardiotoxicity. Human trials are needed to confirm safety and efficacy in this setting.

Related but Distinct - Ketogenic Diets: Ketogenic diets share some metabolic mechanisms with fasting by lowering glucose and insulin. Meta-analyses show reductions in blood sugar, but clinical outcomes in cancer remain mixed and inconclusive. Importantly, ketogenic diets are not the same as fasting and should be evaluated separately.

# Approaches You'll Hear About (and How an Integrative Team Might Use Them)

A) Gentle Circadian Fast (Good Default)

- What it is: 12–14 hours overnight (for example, finishing dinner at 7:00 pm and eating breakfast at 8:00–9:00 am).
- When to use: Often acceptable during radiation or chemotherapy if weight is stable and calorie/protein intake remains adequate.
- Evidence: Observational studies suggest nightly fasts of 13 hours or more may improve metabolic health and lower recurrence risk in certain cancers, such as breast cancer.

B) Time-Restricted Eating (TRE)

- What it is: A daily eating window, typically 14:10 or 16:8 (14 or 16 hours fasting, 10–8 hours eating).
- When to use: Suitable on non-treatment days for metabolically healthy, weight-stable patients.
- Considerations: Protein (≥1.0–1.2 g/kg/day) and calories must be prioritized during the eating window. Shorter fasting windows (14:10) may be more appropriate during intensive treatment phases.
- Evidence: Early oncology studies show feasibility, with potential metabolic benefits.

C) Short-Term Fasting (STF) with Chemotherapy

- What it is: A fasting period of 48–72 hours before chemotherapy, with water or ≤200 calories/day, sometimes extending 24 hours post-treatment.
- When to use: Only under strict medical supervision, as this is not standard of care.
- Considerations: Water-only fasting can be physically and emotionally difficult for many patients.
- Evidence: Small trials suggest reduced side effects and less DNA damage to healthy cells.

D) Fasting-Mimicking Diet (FMD) Cycles with Chemotherapy

- What it is: A plant-based, very low-calorie, low-protein diet for 3 days before chemotherapy, continuing through treatment day.
- When to use: Cycled with each round of chemotherapy, under coordinated guidance from oncology and nutrition teams.
- Benefits: More tolerable than water-only fasting, with evidence of reduced toxicity and possibly improved treatment response.
- Evidence: Randomized controlled trials suggest safety, feasibility, and positive signals in outcomes.

**In active cancer care, fasting should never be started without guidance from the medical team. Screening for malnutrition and cachexia is essential first, and clear "stop rules" should be in place to prevent harm.**

# Putting It Together: A Decision Guide

Prevention & Survivorship

- A good place to begin is with a gentle 12–13+ hour overnight fast.
- If weight and lab markers are stable, some individuals may try a 14:10 time-restricted eating pattern several days per week.
- Pair fasting with protein-forward, plant-rich meals and resistance training to preserve lean muscle mass and support metabolic resilience.

During Chemotherapy

- When appropriate after thorough screening, a fasting-mimicking diet (FMD) coordinated with chemotherapy cycles may be considered.
- Short-term fasting (STF) with water or very low-calorie intake has shown early promise but is best explored only within clinical trials or with highly experienced professional supervision.
- Between cycles, maintaining adequate weight and protein intake is critical to recovery and tolerance of treatment.

During Radiation or Immunotherapy

- The priority here is weight stability and overall nourishment.
- A gentle 12–13 hour circadian fast may be appropriate if tolerated.
- FMD is being investigated for potential synergy with immunotherapy in preclinical work, though human evidence is still forthcoming.

What to Avoid

- Prolonged water fasts (beyond 3–5 days) are not recommended in cancer care due to risks of malnutrition and electrolyte imbalance.
- Juice fasts, especially unpasteurized juices, should be avoided. They are high in sugar, low in protein, lack supportive evidence, and can pose infection risks for immunocompromised patients.

What to Tell Patients & Clinicians

- FMD and gentle circadian fasting appear to be the most promising adjuncts, particularly for reducing chemotherapy-related toxicity and supporting metabolic health. Evidence is encouraging but still evolving.
- Personalization and safety are non-negotiable. Every patient should be screened for malnutrition or cachexia risk before attempting fasting protocols.
- Coordination across disciplines is key. Oncology, naturopathic, functional, and integrative practitioners all have valuable roles in tailoring safe, effective fasting approaches that respect both the evidence and the patient's unique terrain.
- When in doubt, choose the least restrictive option that supports adequate protein, calorie intake, and quality of life.

# Find resources and stay connected:

# IMAhealth.org

Help make resources like this possible.

Donate Today!

IMAhealth.org/donate

INDEPENDENT™ MEDICAL ALLIANCE